Cognis Signs Exclusive Licensing Agreement for Natual ASA's Tonalin® CLA

Cognis Aims to Further Expand Tonalin® CLA into Dietary
Supplement, Food Ingredient, Pharmaceutical and Cosmetic Markets
(“the Key Markets”)

Dusseldorf, Aug.15, 2002 – Cognis, a global specialty chemicals and nutritional ingredients company, and Natural ASA, a Norwegian research and development company, announced today that they have signed an agreement effective Sept. 1, 2002 which grants Cognis an exclusive license in the Key Markets, under Natural’s Conjugated Linoleic Acid (CLA) intellectual property, technology, and know-how, and an exclusive license for the use of the Tonalin® trademark. Conjugated Linoleic Acid, “CLA”, has been shown to be a beneficial fatty acid which is not synthesized by the human body and which must therefore be consumed in the diet. Tonalin® CLA, a well-studied, high CLA content formulation, is primarily marketed today as a dietary supplement with benefits for lean body mass management. The signing of this licensing agreement is a consequence of the Memorandum of Understanding that was announced April 24, 2002.

Natural ASA is the world’s leading supplier of CLA and parent company of Natural Inc., based in Vernon Hills, IL. Patent rights licensed exclusively to Natural from the Wisconsin Alumni Research Foundation (WARF) are part of the agreement. WARF, a not-for-profit organization based in Madison, offers intellectual property management services to the faculty of the University of Wisconsin.

“Cognis is committed to building the Tonalin® mark’s excellent brand equity on a worldwide basis in the dietary supplement, food ingredient, pharmaceutical and cosmetic markets,” said Paul Allen, Group Vice President, Cognis Nutrition and Health. “We are dedicated to funding new research and clinical studies to further develop the science for Tonalin® CLA in the Key Markets,” added Allen. In addition to its scientific program, Cognis is planning an advertising and public relations campaign to strengthen the Tonalin® brand name’s visibility among consumers.

This agreement is mutually advantageous for Cognis and Natural. Cognis is seeking to build its product portfolio of nature-based ingredients for a variety of markets. Natural ASA was seeking an international company operating in the relevant markets to take over the global commercial development of CLA through licensing agreements. Calling Cognis “the ideal licensing partner”, Natural ASA selected Cognis for its scope of expertise in foods, dietary supplements, cosmetics and pharmaceuticals.

Cognis and Natural ASA are collaborating to ensure a seamless transfer of Natural’s portfolio of Tonalin® CLA under Cognis’ Nutrition and Health Division. Cognis will assume global sales responsibility on September 1, 2002.

For information in North America about Tonalin® brand CLA after September 1, call 1-800-673-3702 to place an order, e-mail [email protected], or fax 513-482-3576. For information in Europe about Tonalin® brand CLA after September 1, call +49-211-7940-9692, e-mail [email protected], or fax +49-211 798-2390. For information in Asia Pacific about Tonalin® brand CLA after September 1, call +61-3-9584-4588.

In the interim, customers should continue to contact their Natural sales representative for assistance.

About CLA: CLA is a polyunsaturated, conjugated fatty acid that is a natural part of the human diet through its presence in meat and dairy products. The CLA content of natural dairy products has fallen over time, and the human body now needs to supplement its consumption of CLA from other sources. Natural has developed and patented a number of CLA-containing substances, and expects to see CLA used in the future for preventive medical purposes.

About Cognis:

Cognis ( is a worldwide supplier of innovative specialty chemicals and nutritional ingredients with almost 9,100 employees in close to 50 countries all around the world. The company has dedicated its activities to a high level of sustainability and delivers natural source ingredients for food, nutrition and healthcare markets and serves major customers in the cosmetics, detergents and cleaners industries. Additionally, Cognis provides solutions for a number of industries such as, coatings and inks, lubricants, textiles and plastics as well as agrosolutions and mining chemicals.

Cognis is owned by the investors the Permira Funds, GS Capital Partners, and the Schroder Ventures Life Sciences Funds. In 2001, Cognis recorded sales of 3.1 billion euros and an operating profit of 174 million euros.

About Natural:

Natural (, headquartered in Oslo, Norway, is a research and development company positioned between an external research network and the food/animal feed industries. Natural’s objective is to develop high-value bioactive patent-protected lipid products for licensing to global markets. The main markets are producers of animal feed, human food, and dietary supplements around the world. The research network consists of over 150 researchers connected to universities and research organizations, principally in the USA.

Contact at Cognis:

Susanne Sengel, Manager, Cognis Corporate Communications
Phone: +49-211-7940 5431
email: [email protected]

Contact at Natural:

Nils Vogt, Managing Director, Natural ASA
Phone: +47-67 81 72 12
email: [email protected]

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.